News and Announcements
Following a $15.5 million raise, Flamingo AI (ASX: FGO) begin commercialisation
- Published April 20, 2018 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Flamingo AI establishes foundation for long-term growth
- Commercialisation strategy commences
- Fortune 100 US Insurer Liberty Mutual goes live with Flamingo AI’s Virtual Assistant
- New Sales and Product executives hired – Sales strategy connected
Following the raising of $15.5 m in the previous Quarter, during Q3FY18 the Company has been highly active in shifting the focus of the business from product development to commercialisation. In addition to progressing existing clients, significant work has been conducted in establishing a strong sales and commercial capability to focus the Company on revenue generation.
To read the full ASX announcement, please click here.
About Flamingo AI (ASX: FGO)
Based in NYC and Sydney, Flamingo is an enterprise technology (SaaS) company in the emerging fields of Machine Learning and Conversational Commerce that helps businesses to automate online customer experiences for financial services. Flamingo provides a suite of AI powered Virtual Customer Assistants helping businesses to improve online sales conversion rates, customer experiences and reduce service costs. Our Virtual Customer Assistants, powered by Flamingo’s AI ‘ROSIE’ & ‘MAGGIE’, seamlessly combine chat, smart workflow, natural language processing and machine learning to automatically guide your customers through their online sales or service journey and help them to achieve what they set out to do. This means convenient, more personalised and faster online customer experiences.
Flamingo was acquired by ASX listed Cre8tek Limited in June 2016. The company’s ordinary shares are traded on the Australian Securities Exchange (ASX) under the ticker code CR8.
Company Updates
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
The Light Fantastic: Why Invion’s Photodynamic Therapy May Be Attracting Big Pharma’s Attention
Invion Limited is challenging the status quo in oncology with its Photosoft™ platform, a precision therapy that uses light-activated molecules to selectively target cancer cells. By transforming the body’s own immune response and addressing the high costs of current cancer treatments, Invion is positioning itself as a transformative player in the biotech sector. With clinical trials underway and strong institutional partnerships, the company is bridging the gap between scientific breakthrough and accessible, scalable patient care.
From Outback to Boardroom: How SWAN Systems is Codifying Water Stewardship
From the arid deserts of Australia to the boardrooms of global tech giants, SWAN Systems is redefining water efficiency. By bridging the gap between field-level agronomics and autonomous irrigation control, the company is proving that “water-positive” targets can be met with science, data, and a 10x ROI commitment.
Backed By Leading Investment Groups and Family Offices
